Allogene Therapeutics Stock Cash And Equivalents
| ALLO Stock | USD 2.05 0.13 5.96% |
Allogene Therapeutics fundamentals help investors to digest information that contributes to Allogene Therapeutics' financial success or failures. It also enables traders to predict the movement of Allogene Stock. The fundamental analysis module provides a way to measure Allogene Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allogene Therapeutics stock.
Allogene | Cash And Equivalents |
Allogene Therapeutics Company Cash And Equivalents Analysis
Allogene Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Allogene Therapeutics Cash And Equivalents | 490.49 M |
Most of Allogene Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Allogene Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Allogene Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Allogene Therapeutics is extremely important. It helps to project a fair market value of Allogene Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Allogene Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allogene Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allogene Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Allogene Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Allogene Therapeutics has 490.49 M in Cash And Equivalents. This is 40.25% lower than that of the Biotechnology sector and 9.7% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 81.85% higher than that of the company.
Allogene Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allogene Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allogene Therapeutics could also be used in its relative valuation, which is a method of valuing Allogene Therapeutics by comparing valuation metrics of similar companies.Allogene Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Allogene Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Allogene Therapeutics from analyzing Allogene Therapeutics' financial statements. These drivers represent accounts that assess Allogene Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allogene Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 3.0B | 2.0B | 900.4M | 503.8M | 579.3M | 550.3M | |
| Enterprise Value | 2.1B | 1.3B | 419.0M | 515.7M | 593.1M | 1.2B |
Allogene Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Allogene Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Allogene Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Allogene Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 249.61 M | ||||
| Shares Outstanding | 209.67 M | ||||
| Shares Owned By Insiders | 18.35 % | ||||
| Shares Owned By Institutions | 80.69 % | ||||
| Number Of Shares Shorted | 33.66 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 0.98 X | ||||
| Price To Sales | 10,630 X | ||||
| Revenue | 95 K | ||||
| Gross Profit | (201.94 M) | ||||
| EBITDA | (300.29 M) | ||||
| Net Income | (327.26 M) | ||||
| Cash And Equivalents | 490.49 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 95.12 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 11.42 X | ||||
| Book Value Per Share | 2.21 X | ||||
| Cash Flow From Operations | (237.73 M) | ||||
| Short Ratio | 7.61 X | ||||
| Earnings Per Share | (1.55) X | ||||
| Price To Earnings To Growth | (4.18) X | ||||
| Target Price | 9.23 | ||||
| Number Of Employees | 232 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 457.08 M | ||||
| Total Asset | 642.84 M | ||||
| Retained Earnings | (1.56 B) | ||||
| Working Capital | 422.04 M | ||||
| Current Asset | 418.72 M | ||||
| Current Liabilities | 26.36 M | ||||
| Net Asset | 642.84 M |
About Allogene Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allogene Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allogene Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allogene Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock: Check out Allogene Therapeutics Piotroski F Score and Allogene Therapeutics Altman Z Score analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.